**P113 INDETERMINATE IGRA RESULTS PRIOR TO ANTI-TNF THERAPY: STABLE STATE TESTING MAY BE IMPORTANT FOR IMMUNE-MEDIATED INFLAMMATORY DISORDERS**

1W Ibrahim, 1Y Abunga, 1J Mamo, 1S Beck, 1SO Brij. 1Peterborough and Stamford NHS Hospitals Foundation Trust, Peterborough, UK; 2University Hospital Southampton NHS Foundation Trust, Southampton, UK

10.1136/thoraxjnl-2016-209333.256

**Introduction** Screening for active tuberculosis (TB) and latent TB infection (LTBI) is mandatory prior to the initiation of anti-TNF therapy in patients with immune-mediated inflammatory diseases (IMID). In 2010, our local guideline included QuantiFERON®-TB Gold (QFT) as well as clinical risk stratification. However, indeterminate QFT results were increasingly identified in this population, higher than that observed in other published series.

**Aims** To identify patient and IMID characteristics that may be contributing to indeterminate QFT results and LTBI diagnostic uncertainty.

**Methods** We conducted a retrospective study of all patients that had received at least one dose of anti-TNF since 2010. Data obtained included patient demographics, TB risk stratification and QFT results.
RESULTS 181 patients (M:F 87:94; age range 11–83; average age 44.8 years) had received at least one dose anti-TNF and were included in this study (see Table). The majority of patients had colitis (n = 143; 79%). 52 patients (28.7%) did not have a documented QFT or IGRA (interferon gamma release assay) result. LTBI was diagnosed in 8 (6.2%) with reactive QFT of whom 7 completed chemoprophylaxis and 1 was referred for further investigation and treatment elsewhere. 95 (73.6%) were QFT non-reactive. 26 (20.2%) were QFT indeterminate, all of whom had a diagnosis of colitis. Colitis patients were more likely to be QFT indeterminate if they were tested at the time of rescue anti-TNF with or without surgery (RR 5.71; 95% CI: 2.49–13.09; p < 0.0001). 2 patients who received rescue anti-TNF and were subsequently found to be QFT reactive, successfully completed LTBI chemoprophylaxis.

Conclusion The rate of indeterminate QFT results is higher than expected in our cohort of patients with colitis who require rescue anti-TNF therapy and is likely to be related to the timing of testing. If QFT testing is undertaken, this should be performed when patients are at stable state and not at the time of inflammatory crisis.

Methods We reviewed written and electronic records for all contacts screened in Leeds in 2015. NICE 2016 guidance was applied retrospectively to analyse the impact of each recommendation and the guidance as a whole.

RESULTS 216 contacts were screened. Full records were available for 193. 14 were treated for LTBI, 2 for active TB, and 6 contacts over 35 had X-ray follow up. 34 had TST > 10 mm, an additional 13 had TST 5–9 mm. Of 34 with TST > 10 mm, 14 (41%) had positive IGRA. 97/193 (50%) were contacts of extrapulmonary tuberculosis. 4 of these were treated for LTBI, but 21 had TST > 5 mm.

Using TST > 5 mm cut off would increase the number of IGRA tests from 34 to 46. Treating on basis of TST alone would increase the number given chemoprophylaxis from 14 to 46. Stopping screening for contacts of extrapulmonary cases would reduce the number screened by 50% and the number treated from 46 to 29. However, this would be at the cost of missing at least 4/14 LTBI with positive IGRA.

Conclusion Adopting the new NICE guidance in full would reduce the number screened but significantly increase the numbers treated for LTBI. Using the 2 step test with a TST cut off of 5mm would modestly increase the number of IGRA tests but would be unlikely to have a large impact on the number treated. Stopping screening for contacts of extrapulmonary TB would reduce the screening workload by 50% but reduce the number of LTBI cases diagnosed by 29%.